Navigation Links
Dr. Ben Goldacre to Keynote PhUSE Annual Conference

Brussels, Belgium (PRWEB) February 07, 2013

PhUSE, a non-profit, volunteer-supported, community of professionals who are passionate about advancement of clinical information, is proud to announce that Dr. Ben Goldacre will present the Keynote at the 2013 PhUSE Annual Conference. The 2013 conference focus is ‘Patient Centricity’ in the pharmaceutical world.

As a physician and academic writer Doctor Ben Goldacre will speak to the PhUSE community about how patient centric thinking will help to bring efficacious new drugs to patients. In his latest book "Bad Pharma" Doctor Ben Goldacre gives a critical insight into the 600 billion dollar global pharmaceutical industry. In his keynote Doctor Goldacre will share his views on the process of new drug approval. He will tell the PhUSE community how flaws in the planning, conduct and publication of studies conducted by the pharmaceutical industry can harm the life of patients.

In his keynote for PhUSE, Doctor Goldacre will address the interests of all involved parties: the patients, pharmaceutical drug companies, regulatory bodies and payers.

Discussion groups for conference attendees will expand upon the themes of the keynote, giving attendees the opportunity to learn and share knowledge about creating better outcomes for patients through their work with clinical trial data.

Registration for the conference is open. Sponsorship opportunities are available.

About Doctor Goldacre:
Ben Goldacre is an award-winning writer, broadcaster, and medical doctor who specializes in unpicking scientific claims made by scaremongering journalists, government reports, pharmaceutical corporations, PR companies and quacks. He was trained in Medicine at Oxford and London, and currently works as an academic in epidemiology. Ben wrote the weekly Bad Science column in the Guardian from 2003-2011. Bad Science the book (4th Estate) has sold over half a million copies worldwide, reached #1 in the paperback non-fiction charts, and is being published in 25 languages. In his new book, Bad Pharma (4th Estate, September 2012) Ben puts the $600bn global pharmaceutical industry under the microscope. What he reveals is a fascinating, terrifying mess.

About PhUSE
PhUSE, Share – Contribute – Advance, provides the industry with the premier platform for creating and sharing ideas, tools and standards around data, statistical and reporting technologies; PhUSE is a non-profit, volunteer-supported, community of professionals who are passionate about advancement of clinical information. Since its inception, PhUSE has expanded from its roots as a conference for European Statistical Programmers, to a global platform for the discussion of topics encompassing the work of Data Managers, Biostatisticians, Statistical Programmers and eClinical IT professionals.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. PAREXEL Chairman and CEO to Deliver Keynote at MassBio CRO/CMO Symposium
2. Specialty Chemical Forum 2012 Kicks Off in Houston; AkzoNobels Frank Sherman Delivers Keynote Address
3. National Defense Industrial Association's (NDIA) 2012 Biosurveillance Conference To Feature Keynote Speaker Laurie Garrett, Pulitzer Prize Winner and Bestselling Author
4. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
5. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
6. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
7. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
8. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
9. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
10. 15-Minute Data From Phase 3 Study of Avanafil Featured as a Late Breaking Abstract at SMSNA Annual Meeting
11. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
Post Your Comments:
(Date:10/12/2015)...  Rebiotix Inc. today announced that U.S. Food ... Microbiota Restoration Therapy (MRT) RBX2660 as a Breakthrough ... difficile (C diff) infection, a challenging to ... in the U.S. annually. 1 Rebiotix is ... to revolutionize the treatment of debilitating GI diseases ...
(Date:10/12/2015)... 12, 2015  Patara Pharma, a clinical-stage biotechnology ... diseases and conditions, today announced the closing of ... Concurrent with the close of its sale of ... and Security Agreement with Silicon Valley Bank whereby ... Patara will use the funds from the financing ...
(Date:10/12/2015)... ... October 12, 2015 , ... Dr. Carl Peck, MD, Chairman ... firm as a Premier Expert consultant. NDA Partners Premier Experts are top ... to the company's clients. Premier Experts collaborate to design and implement critical ...
(Date:10/10/2015)... 10 octobre 2015 Le 8 octobre, l,honorable Doris ... Registre du Congrès sa déclaration de soutien à ... autour du plasma (IPAW), qui se tiendra du ... Plasma Protein Therapeutics Association (PPTA) et ... , Sensibiliser l,opinion publique mondiale autour du ...
Breaking Biology Technology:
(Date:9/30/2015)... 30, 2015  The global glucose monitoring device and diabetes ... says a new report on the industry from Kalorama Information. Sales ... the market, followed by continuous glucose monitoring and sensor segment, ... market for these products in its latest report, The ... , ...
(Date:9/29/2015)... , Sept. 29, 2015  iDAvatars is excited to ... introduce its product to market. The official announcement was recently ... Economy event in San Francisco , ... platform powered by IBM Watson. "It is both ... first 100 companies to bring to market the cognitive power ...
(Date:9/28/2015)... 28, 2015  The monitoring of vital signs, ... temperature, is an essential component of patient assessment. ... deterioration in a patient,s condition. However, in general ... typically taken during routine observation rounds only once ... deteriorates between these observation rounds, the warning signs ...
Breaking Biology News(10 mins):